Tuberculosis, sometimes known as TB, is an infectious illness caused by various mycobacteria strains, the most prevalent of which is Mycobacterium tuberculosis (Mtb). TB is the most common contagious bacterial agent-related cause of death globally. According to the World Health Organization (WHO), about one-third of the world's population is infected with Mtb, with two billion people worldwide affected. As a result, despite the availability of effective anti-TB medications, tuberculosis remains a severe worldwide public health problem, necessitating the ongoing search for novel anti-TB therapies and therapy regimens. Preexisting anti-TB medications have been modified considerably, resulting in the development of innovative, effective, and non-toxic anti-TB agents. Despite more than a century of research, tuberculosis (TB) remains the most common infectious illness in humans, with an estimated 9 million new cases and 1.5 million deaths each year. The anti-tubercular effects of a novel family of nitrogen-containing heterocyclic compounds known as substituted-pyridazines were investigated. Some of these derivatives were discovered to be active against Mycobacterium TB, and their antitubercular activities were compared to those of Rifampicin, Pyrimethamine, and Cycloserine, which are all conventional antitubercular medications. These findings were backed up by the fact that pyridazine derivatives looked to be a new leading antitubercular structure, making it a viable candidate for further therapeutic development.

Antitubercular, Heterocyclic, Pyridazine, New Drugs.